Has-miR-107及ZFPM2在胰腺癌中的潜在研究价值
The Potential Research Value of Has-miR-107 and ZFPM2 in Pancreatic Cancer
DOI: 10.12677/acm.2025.153589, PDF,   
作者: 刘兆雄：内蒙古医科大学第一临床医学院，内蒙古 呼和浩特；内蒙古医科大学附属医院肝胆外科，内蒙古 呼和浩特；赵海平*：内蒙古医科大学附属医院肝胆外科，内蒙古 呼和浩特
关键词: 胰腺癌；靶向治疗；miRNA；ZFPM2；Pancreatic Cancer； Targeted Therapy； miRNA； ZFPM2
摘要: 胰腺癌是预后极差的一种消化道恶性肿瘤，因其发现较晚，对于放化疗不甚敏感，导致5年生存率不足5%，随着科学技术的发展，miRNA在癌症中的关键作用已被证实。miRNA也迅速成为开发新型抗癌疗法的有前途的靶标，其中miR-107及其下游的可能靶基因ZFPM2已被发现与多种癌症存在关系，但在胰腺癌的研究仍有空缺，对于改善目前胰腺癌早期发现及治疗困境具有一定的潜在价值。本文通过综述现有的关于miR-107与ZFPM2在其他肿瘤中的研究现状，为胰腺癌的早期发现及靶向治疗提供新的思路。
Abstract: Pancreatic cancer is a highly malignant digestive tract tumor with an extremely poor prognosis. Due to its late detection and limited sensitivity to radiotherapy and chemotherapy, the 5-year survival rate is less than 5%. With the advancement of science and technology, the critical role of miRNA in cancer has been confirmed. miRNA has rapidly emerged as promising targets for the development of novel anti-cancer therapies. Among them, miR-107 and its potential downstream target gene ZFPM2 have been found to be associated with various cancers, but research on their roles in pancreatic cancer remains limited. They hold potential value for improving the current challenges in early detection and treatment of pancreatic cancer. This article reviews the existing research on miR-107 and ZFPM2 in other tumors, aiming to provide new insights for early detection and targeted therapy of pancreatic cancer.
文章引用：刘兆雄, 赵海平. Has-miR-107及ZFPM2在胰腺癌中的潜在研究价值[J]. 临床医学进展, 2025, 15(3): 75-82. https://doi.org/10.12677/acm.2025.153589

参考文献

[1] Wood, L.D., Canto, M.I., Jaffee, E.M. and Simeone, D.M. (2022) Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology, 163, 386-402.e1. [Google Scholar] [CrossRef] [PubMed]
[2] Thorsen, S.B., Obad, S., Jensen, N.F., Stenvang, J. and Kauppinen, S. (2012) The Therapeutic Potential of MicroRNAs in Cancer. The Cancer Journal, 18, 275-284. [Google Scholar] [CrossRef] [PubMed]
[3] Luo, Z., Zheng, Y. and Zhang, W. (2018) Pleiotropic Functions of miR107 in Cancer Networks. OncoTargets and Therapy, 11, 4113-4124. [Google Scholar] [CrossRef] [PubMed]
[4] Sizemore, G.M., Balakrishnan, S., Thies, K.A., Hammer, A.M., Sizemore, S.T., Trimboli, A.J., et al. (2018) Stromal PTEN Determines Mammary Epithelial Response to Radiotherapy. Nature Communications, 9, Article No. 2783. [Google Scholar] [CrossRef] [PubMed]
[5] Wang, L., Yang, C., Liu, X., Wang, L. and Kang, F. (2018) B7-H4 Overexpression Contributes to Poor Prognosis and Drug-Resistance in Triple-Negative Breast Cancer. Cancer Cell International, 18, Article No. 100. [Google Scholar] [CrossRef] [PubMed]
[6] Pan, H., Peng, H., Dai, Y., Han, B., Yang, G., Jiang, N., et al. (2023) Effects of miR-107 on Breast Cancer Cell Growth and Death via Regulation of the PTEN/AKT Signaling Pathway. Journal of Oncology, 2023, Article ID: 1244067. [Google Scholar] [CrossRef] [PubMed]
[7] Zhou, J., Sun, X., Zhang, X., Yang, H., Jiang, Z., Luo, Q., et al. (2022) miR-107 Is Involved in the Regulation of NEDD9-Mediated Invasion and Metastasis in Breast Cancer. BMC Cancer, 22, Article No. 533. [Google Scholar] [CrossRef] [PubMed]
[8] Wei, X., Lei, Y., Li, M., Zhao, G., Zhou, Y., Ye, L., et al. (2020) miR-107 Inhibited Malignant Biological Behavior of Non-Small Cell Lung Cancer Cells by Regulating the STK33/ERK Signaling Pathway in Vivo and Vitro. Journal of Thoracic Disease, 12, 1540-1551. [Google Scholar] [CrossRef] [PubMed]
[9] Tian, S., Yu, Y., Huang, H., Xu, A., Xu, H. and Zhou, Y. (2020) Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta‐Analysis. BioMed Research International, 2020, Article ID: 4540312. [Google Scholar] [CrossRef] [PubMed]
[10] Rezaei, N., Jafari, D., Noorbakhsh, F., Delavari, A., Tavakkoli-Bazzaz, J., Farashi-Bonab, S., et al. (2020) Expression Level of Long Noncoding RNA NKILAmiR103-miR107 Inflammatory Axis and Its Clinical Significance as Potential Biomarker in Patients with Colorectal Cancer. Journal of Research in Medical Sciences, 25, 41. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, Y., Zhang, B., Zhu, Y., Zhang, Y., Li, L., Shen, T., et al. (2022) hsa_circ_0000523/miR‑let‑7b/METTL3 Axis Regulates Proliferation, Apoptosis and Metastasis in the HCT116 Human Colorectal Cancer Cell Line. Oncology Letters, 23, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, H., Lin, Y., Chung, H., Lang, Y., Lin, C., Huang, J., et al. (2012) miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. Cancer Research, 72, 3631-3641. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, Q., Huang, J., Yan, W., Liu, Z., Liu, S. and Fang, W. (2023) FGFR Families: Biological Functions and Therapeutic Interventions in Tumors. MedComm, 4, e367. [Google Scholar] [CrossRef] [PubMed]
[14] Sharma, P., Kaushik, V., Saraya, A. and Sharma, R. (2023) Aberrant Expression of FGFRL1 in Esophageal Cancer and Its Regulation by miR-107. Asian Pacific Journal of Cancer Prevention, 24, 1331-1341. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, H., Yang, M., Zhang, Y., Yang, Z., Chen, Z., Xie, Y., et al. (2021) The Effect of miR-539 Regulating TRIAP1 on the Apoptosis, Proliferation, Migration and Invasion of Osteosarcoma Cells. Cancer Cell International, 21, Article No. 227. [Google Scholar] [CrossRef] [PubMed]
[16] Na, C., Li, X., Zhang, J., Han, L., Li, Y., Zhang, H., et al. (2019) miR-107 Targets TRIAP1 to Regulate Oral Squamous Cell Carcinoma Proliferation and Migration. International Journal of Clinical and Experimental Pathology, 12, 1820-1825.
[17] Yan, J., Dai, L., Yuan, J., Pang, M., Wang, Y., Lin, L., et al. (2022) miR-107 Inhibits the Proliferation of Gastric Cancer Cells in Vivo and in Vitro by Targeting TRIAP1. Frontiers in Genetics, 13, Article 855355. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, H., Li, C., Lin, Y., Wang, T., Chen, M., Su, Y., et al. (2021) Hsa-miR-107 Regulates Chemosensitivity and Inhibits Tumor Growth in Hepatocellular Carcinoma Cells. Aging, 13, 12046-12057. [Google Scholar] [CrossRef] [PubMed]
[19] Han, S., Cao, D., Sha, J., Zhu, X. and Chen, D. (2020) LncRNA ZFPM2‐AS1 Promotes Lung Adenocarcinoma Progression by Interacting with UPF1 to Destabilize ZFPM2. Molecular Oncology, 14, 1074-1088. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, D., Wang, M., Jiang, X. and Xiong, Z. (2022) Comprehensive Analysis of ZFPM2-AS1 Prognostic Value, Immune Microenvironment, Drug Sensitivity, and Co-Expression Network: From Gastric Adenocarcinoma to Pan-Cancers. Discover Oncology, 13, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[21] Ghorbanoghli, Z., Nieuwenhuis, M.H., Houwing-Duistermaat, J.J., Jagmohan-Changur, S., Hes, F.J., Tops, C.M., et al. (2016) Colorectal Cancer Risk Variants at 8q23.3 and 11q23.1 Are Associated with Disease Phenotype in APC Mutation Carriers. Familial Cancer, 15, 563-570. [Google Scholar] [CrossRef] [PubMed]
[22] Luo, Y., Wang, X., Ma, L., Ma, Z., Li, S., Fang, X., et al. (2020) Bioinformatics Analyses and Biological Function of LncRNA ZFPM2-AS1 and ZFPM2 Gene in Hepatocellular Carcinoma. Oncology Letters, 19, 3677-3686. [Google Scholar] [CrossRef] [PubMed]
[23] Ma, T., Cai, X., Wang, Z., Huang, L., Wang, C., Jiang, S., et al. (2017) miR-200c Accelerates Hepatic Stellate Cell-Induced Liver Fibrosis via Targeting the FOG2/PI3K Pathway. BioMed Research International, 2017, Article ID: 2670658. [Google Scholar] [CrossRef] [PubMed]
[24] Manuylov, N.L., Smagulova, F.O. and Tevosian, S.G. (2007) Fog2 Excision in Mice Leads to Premature Mammary Gland Involution and Reduced Esr1 Gene Expression. Oncogene, 26, 5204-5213. [Google Scholar] [CrossRef] [PubMed]
[25] Qiang, Z., Jubber, I., Lloyd, K., Cumberbatch, M. and Griffin, J. (2023) Gene of the Month: GATA3. Journal of Clinical Pathology, 76, 793-797. [Google Scholar] [CrossRef] [PubMed]
[26] Song, Z., Gao, S., Liu, Y.M., et al. (2020) EphA3 Promotes the Proliferation of NPC Cells through Negatively Regulating the Ability of FOG2. European Review for Medical and Pharmacological Sciences, 24, 6735-6743.
[27] Yasinjan, F., Xing, Y., Geng, H., Guo, R., Yang, L., Liu, Z., et al. (2023) Immunotherapy: A Promising Approach for Glioma Treatment. Frontiers in Immunology, 14, Article 1255611. [Google Scholar] [CrossRef] [PubMed]
[28] Tsang, S., Mei, L., Wan, W., Li, J., Li, Y., Zhao, C., et al. (2015) Glioma Association and Balancing Selection of ZFPM2. PLOS ONE, 10, e0133003. [Google Scholar] [CrossRef] [PubMed]
[29] 丁岩, 王飞, 赵海平. 上皮间充质转化在胰腺疾病中的研究进展[J]. 中国临床研究, 2023, 36(2): 242-246.
[30] Mittal, V. (2018) Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology: Mechanisms of Disease, 13, 395-412. [Google Scholar] [CrossRef] [PubMed]
[31] Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. (2015) Epithelial-to-Mesenchymal Transition Is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer. Nature, 527, 525-530. [Google Scholar] [CrossRef] [PubMed]
[32] Li, J., Lu, R., Yang, K. and Sun, Q. (2022) CircCCT3 Enhances Invasion and Epithelial-Mesenchymal Transition (EMT) of Non-Small-Cell Lung Cancer (NSCLC) via the miR-107/Wnt/FGF7 Axis. Journal of Oncology, 2022, Article ID: 7020774. [Google Scholar] [CrossRef] [PubMed]
[33] Yao, J., Yang, Z., Yang, J., Wang, Z. and Zhang, Z. (2021) Long Non-Coding RNA FEZF1-AS1 Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma via Targeting miR-107/Wnt/β-Catenin Axis. Aging, 13, 13726-13738. [Google Scholar] [CrossRef] [PubMed]
[34] 陈思宇, 汪献旺. 靶向PI3K信号通路抑制剂在胰腺癌治疗中的研究进展[J]. 实用医学杂志, 2023, 39(9): 1190-1194.
[35] Peng, Y., Wang, Y., Zhou, C., Mei, W. and Zeng, C. (2022) PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Frontiers in Oncology, 12, Article 819125. [Google Scholar] [CrossRef] [PubMed]
[36] Mehra, S., Deshpande, N. and Nagathihalli, N. (2021) Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. Cancers, 13, Article 4434. [Google Scholar] [CrossRef] [PubMed]
[37] Liu, X., Xu, Y., Zhou, Q., Chen, M., Zhang, Y., Liang, H., et al. (2017) PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment. Future Oncology, 14, 665-674. [Google Scholar] [CrossRef] [PubMed]
[38] Faes, S. and Dormond, O. (2015) PI3K and AKT: Unfaithful Partners in Cancer. International Journal of Molecular Sciences, 16, 21138-21152. [Google Scholar] [CrossRef] [PubMed]
[39] Wiese, W., Barczuk, J., Racinska, O., Siwecka, N., Rozpedek-Kaminska, W., Slupianek, A., et al. (2023) PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers, 15, Article 5297. [Google Scholar] [CrossRef] [PubMed]
[40] Ediriweera, M.K., Tennekoon, K.H. and Samarakoon, S.R. (2019) Role of the PI3K/Akt/mTOR Signaling Pathway in Ovarian Cancer: Biological and Therapeutic Significance. Seminars in Cancer Biology, 59, 147-160. [Google Scholar] [CrossRef] [PubMed]
[41] 王皓帆. 保守的microRNA-miR-8/miR-200及其靶分子USH/FOG2通过调控PI3K水平控制生长过程[J]. 中国病理生理杂志, 2010, 26(6): 1114.
[42] Sorrentino, A., Federico, A., Rienzo, M., Gazzerro, P., Bifulco, M., Ciccodicola, A., et al. (2018) PR/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas. International Journal of Molecular Sciences, 19, Article 3250. [Google Scholar] [CrossRef] [PubMed]

为你推荐